IP Library Granted Patent US 10,562,866
Granted Patent B2
US 10,562,866 · App. 15/568,550 · Granted Feb 18, 2020

Amorphous trisodium sacubitril valsartan and a process for the preparation thereof

Inventors: Vellanki Sivaram Prasad (Telangana, IN); Arabinda Sahu (Telangana, IN); Siva Koteswara Rao Prathi (Telangana, IN); Lakshmana Rao Ampolu (Telangana, IN); Ramakoteswara Rao Jetti (Telangana, IN); Aggi Ramireddy Bommareddy (Telangana, IN); Neelima Bhagavatula (Telangana, IN); Nitin Ashok Shimpi (Telangana, IN)
Assignee: Mylan Laboratories Limited
C07D257/04C07C231/12C07C231/24C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,562,866
App. No.
15/568,550
Granted
Feb 18, 2020
Kind
B2
Abstract

The amorphous form of trisodium sacubitril valsartan and methods for the preparation thereof are disclosed herein.

Claims (32)

1. A process for the preparation of amorphous trisodium sacubitril valsartan, comprising the steps of:

a. dissolving trisodium sacubitril valsartan in a solvent selected from the group consisting of an alcohol solvent, water, and mixtures thereof;

b. removing the solvent; and

c. isolating amorphous trisodium sacubitril valsartan.

2. The process according to claim 1 , wherein the alcohol solvent is selected from the group consisting of methanol, ethanol, propanol, isopropanol and mixtures thereof.

3. A process for the preparation of amorphous trisodium sacubitril valsartan, comprising the steps of:

a. dissolving sacubitril valsartan trisodium hemipentahydrate in a first solvent to form a solution, wherein dissolving trisodium sacubitril valsartan is achieved at an elevated temperature from about 90° C. to about 110° C.;

b. adding a second solvent to the solution; and

c. isolating amorphous trisodium sacubitril valsartan.

4. The process according to claim 3 , wherein the first solvent is a polar solvent selected from the group consisting of an alcohol solvent, an ester solvent, a ketone solvent, and mixtures thereof and the second solvent is a non-polar solvent selected from the group consisting of an ether solvent, a hydrocarbon solvent, and mixtures thereof.

5. The process according to claim 4 , wherein the alcohol solvent is selected from the group consisting of methanol, ethanol, isopropanol, and mixtures

thereof; the ester solvent is selected from the group consisting of methyl acetate, ethyl acetate, isopropyl acetate, tert-butyl acetate, and mixtures thereof; the ketone solvent is selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, and mixtures thereof; the ether solvent is selected from the group consisting of diethyl ether, diisopropyl ether, methyl tert-butyl ether, and mixtures thereof; and the hydrocarbon solvent is selected from the group consisting of pentane, hexane, heptane, cyclohexane, and mixtures thereof.

6. A process for the preparation of an amorphous form of trisodium sacubitril valsartan comprising the steps of:

a. dissolving sacubitril and valsartan in a solvent to form a solution, wherein the solvent is a polar solvent selected from the group consisting of tetrahydrofuran, acetone, dimethylformamide, ethyl acetate, dimethyl sulfoxide, and mixtures thereof;

b. adding a sodium source to the solution;

c. removing the solvent; and

d. isolating amorphous trisodium sacubitril valsartan.

7. The process according to claim 6 , wherein the solvent is tetrahydrofuran.

8. The process according to claim 6 , wherein the sodium source is selected from the group consisting of sodium hydroxide, sodium alkoxides, and sodium ethylhexanoate.

9. A process for the preparation of amorphous trisodium sacubitril valsartan, comprising the steps of:

a. dissolving sacubitril and valsartan in a first solvent to form a solution;

b. adding a sodium source to the solution;

c. removing the first solvent;

d. adding a second solvent to form a second solution, wherein the second solvent is an organic solvent;

e. adding a third solvent to the second solution, wherein the third solvent is a non-polar solvent; and

f. isolating amorphous trisodium sacubitril valsartan.

10. The process according to claim 9 , wherein the first solvent is a polar solvent selected from the group consisting of an alcohol solvent, an ether solvent, an ester solvent, a ketone solvent, an amide solvent, dimethyl sulfoxide, and mixtures thereof and the second solvent is a polar solvent selected from the group consisting of an alcohol solvent, a ketone solvent, an ester solvent, and mixtures thereof.

11. The process according to claim 10 , wherein each alcohol solvent is selected from the group consisting of methanol, ethanol, isopropanol, and mixtures thereof; the ether solvent is selected from the group consisting of tetrahydrofuran, diethyl ether, 1,4-dioxane, methyl tert-butyl ether, and mixtures thereof; each ester solvent is selected from the group consisting of methyl acetate, ethyl acetate, isopropyl acetate, tert-butyl acetate, and mixtures thereof; each ketone solvent is selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, and mixtures thereof; and the amide solvent is selected from the group consisting of dimethylacetamide, dimethylformamide, and mixtures thereof.

12. The process according to claim 9 , wherein the sodium source is selected from the group consisting of sodium hydroxide, sodium alkoxides, and sodium 2-ethylhexanoate.

13. The process according to claim 9 , wherein the first solvent is removed by evaporation.

14. The process according to claim 9 , wherein the third solvent is a non-polar solvent selected from the group consisting of an alkane, a non-polar ether, and mixtures thereof.

15. The process according to claim 14 , wherein the alkane solvent is selected from the group consisting of n-pentane, n-heptane, n-hexane, and mixtures thereof and the non-polar ether solvent is selected from the group consisting of methyl tert-butyl ether, diethyl ether, diisopropyl ether, and mixtures thereof.

Assignments (3)
CHANGE OF NAME Recorded Jan 12, 2026
From: TIANISH LABORATORIES PRIVATE LIMITED
To: MATRIX PHARMACORP PRIVATE LIMITED
Reel/Frame 074322/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: MYLAN LABORATORIES LIMITED
To: TIANISH LABORATORIES PRIVATE LIMITED
Reel/Frame 068861/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2019
From: PRASAD, VELLANKI SIVARAM; BHAGAVATULA, NEELIMA; AMPOLU, LAKSHMANA RAO; SHIMPI, NITIN ASHOK; SAHU, ARABINDA; PRATHI, SIVA KOTESWARA RAO; JETTI, RAMAKOTESWARA RAO; BOMMAREDDY, AGGI RAMIREDDY
To: MYLAN LABORATORIES LIMITED
Reel/Frame 048571/0605 →
Priority Claims (2)
IN 602/CHE/2015 · Feb 6, 2015 · national
IN 3531/CHE/2015 · Jul 10, 2015 · national
Continuity (1)
Related Publication 20180273493A1 · Sep 27, 2018